Home - National Multiple Sclerosis Society

Skip to navigation Skip to content

Forward This Message to a Friend

* = Required Fields

 

*

 

*

Enter multiple addresses on separate lines or separate them with commas.
(Note: We respect your privacy, addresses you enter below will be added to your Address Book, but will not be used by the organization. For further information, see our Privacy Policy.)

  
   Please leave this field empty

A copy of the message that follows will be sent to the addresses you specify:

Email not displaying correctly? View it in your browser.
enews_image_header2_nov11.jpg

mainstory_subhead_nov11.jpg

Like almost everything else related to the disease, MS pain has many forms and many causes. It warrants exploring many different therapies. Read more in the Winter 2011-12 issue of Momentum, now available online in our interactive digital edition.

Get connected  

Donate Now 

 Find us on Facebook 

YouTube MySpace Twitter


eNews Meet Heading

Ryan Asdourian

Ryan Asdourian, 2011 Volunteer of the Year
 
enews_header_signupnow_nov11_v2.jpg

webcast

From the Frontlines: What's New in MS Research for 2012
 

Early positive results from three phase III clinical trials were shared last month at the world’s largest annual MS research meeting. Two treatments — alemtuzumab (Genzyme) and BG-12 (Biogen Idec) — could be available as early as next year. Read about them and about the more than 1,100 studies presented at this groundbreaking meeting.

Get the in-depth report

 

enews_teaser2_research_nov11.jpgenews_teaser2_title_bacteria_nov11.jpg 

A new study — one of 32 just launched with Society funding — will look at how common bacteria that live in the human body might trigger immune attacks on the nervous system in MS. The Society has just committed $16 million to cutting-edge research in 2012, as part of its comprehensive strategy to stop MS in its tracks, restore function that has been lost, and end the disease forever.

Read more about the funded research

More MS News 

Nov 9: Raleigh America and Bike MS team up

Oct 31: Phase II results published from clinical trial of ocrelizumab in relapsing MS

Oct 24: Fast Forward and Athersys collaborate to support development of MultiStem to treat MS

Read more about these and other recent reports

This communication is partially sponsored through the generous support of Biogen Idec;
EMD Serono and Pfizer, Inc; Novartis Pharmaceuticals Corporation; and Teva Neuroscience, Inc.
 

MS Active Source  MS LifeLinesNovartis Teva Neuroscience

Join a Walk MS Event       Join a Bike MS Event      Shop at the Society Store

National MS Society | View as Web page | Subscribe | Legal Notice/Privacy Policy | Email Preferences | Unsubscribe

MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS.
JOIN THE MOVEMENT®

Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — please
visit our Web site.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.

National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017

This message was sent to  .
To ensure that you continue to receive our emails, please add us to your address book.



Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://main.nationalmssociety.org/ or 1-800-FIGHT-MS (344-4867).

Our postal address is:
National Multiple Sclerosis Society
733 Third Avenue
New York, New York 10017

| | |